America needs more clinics of last resort for patients who can’t get answers - Summary - MDSpire

America needs more clinics of last resort for patients who can’t get answers

  • By

  • Alexandra Sifferlin

  • March 31, 2026

  • 0 min

Share

Objective:

To highlight the importance of the Undiagnosed Diseases Network (UDN) in addressing rare medical conditions and its broader implications for understanding common diseases, as well as the need for more similar clinics across the U.S.

Key Findings:
  • The UDN has successfully diagnosed over 1,000 patients with rare or previously unknown conditions.
  • Roughly 1 in 10 Americans lives with a rare disease, collectively impacting tens of millions.
  • The UDN provides advanced diagnostic tools at no cost to patients, contrasting with traditional healthcare experiences.
  • Government support is essential for the sustainability of rare disease research initiatives like the UDN.
Interpretation:

The UDN serves as a critical resource for patients with undiagnosed rare diseases, offering comprehensive care and fostering trust in the healthcare system, while also serving as a model for future healthcare initiatives.

Limitations:
  • The UDN's capacity is limited and cannot meet the demand for all patients with rare diseases.
  • Funding for rare disease research is vulnerable to political shifts, which could impact the UDN's operations.
Conclusion:

The UDN exemplifies a successful model for addressing rare diseases and should be expanded to more medical centers to improve patient outcomes, with specific recommendations for implementation.

Original Source(s)

America needs more clinics of last resort for patients who can’t get answers

  • by Alexandra Sifferlin

  • March 31, 2026

Related Content

SORS Identifies Preservation Fluids Through Sealed Museum Jars

Portable spatially offset Raman spectroscopy and multivariate models classify historic wet-collection fluids in situ

  • February 13, 2026

  • 3 min
New Collaboration to Automate Cell Therapy Manufacturing with Robotics

Focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technology

  • February 12, 2026

  • 2 min
Refining Single-Cell Metabolomics with Ion Mobility

Ion mobility-resolved mass cytometry expands metabolite coverage across thousands of single cells 

  • February 24, 2026

  • 2 min